Dr. Schnitzer, M.D. has devoted more than 30 years to understanding vascular endothelial cell barrier function and drug delivery in medicine, specifically how best to overcome this barrier to improve therapeutic impact of drugs in cancer, lung and other diseases. His lab currently focuses on drug delivery systems, small animal intravital and whole body imaging, how caveolae function in transport, proteomic mapping of endothelial cell surface and its caveolae in normal and diseased tissues, antibody engineering, nanocarriers, ADCs and new therpaeutics in cancer and lung disease. Dr. Schnitzer is the CEO and founder of Proteogenomics Institute for Systems Medicine. Dr. Schnitzer has a B.S.E. degree in Chemical Engineering from Princeton University and M.D. from University of Pittsburgh and was a postdoctoral fellow at Yale University School of Medicine. He is also an Adjunct Professor at the Institute of Engineering and Medicine at UCSD.